Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers

Klingel, Hanna; Lauen, Maike; Krüttgen, Alex; Imöhl, Matthias; Kleines, Michael

doi:10.7774/cevr.2022.11.1.121

Cited by 8 publications

(4 citation statements)

References 21 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of AEs was higher in the high CD8+ T cells group [ 22 ]. Another study also confirms that the severity of adverse reactions is associated with CD4+ and CD8+ T-cell response in mRNA-1273 vaccinated health care workers [ 23 ]. Based on these results, it is reasonable to assume that the immune processes triggered by the heterologous vaccine, which are different compared to those elicited by the homologous version, may be responsible for the more frequent adverse reactions.…”

Section: Discussionsupporting

confidence: 53%

Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme

et al. 2023

View full text Add to dashboard Cite

Background: It is known that adverse reactions following SARS-CoV-2 vaccinations show a positive correlation with the subsequent antibody titer. However, it is not clear how the adverse reactions following the booster vaccination are related to the antibody levels that can be measured after a 3rd dose. The primary goal of this study was to investigate whether the adverse reactions following the booster vaccination show a correlation with subsequent antibody levels. Methods: Adverse reactions occurring within 7 days after the 3rd vaccination were recorded and the anti-SARS-CoV-2 spike protein immunoglobulin (Ig) level in the venous blood was measured on post-vaccination 14th, 60th and 120th days. Results: A total of 218 volunteers were included in the study. Main findings: (i) The adverse reactions that appeared after the booster dose did not show a positive correlation with the subsequent antibody level, except a correlation in the case of fever; (ii) there were more symptomatic patients in the group receiving heterologous booster vaccine, (iii) fever after the 2nd dose was independently associated with a reduction in the likelihood of COVID-19 positivity after the booster dose. Conclusion: No adverse reactions, but fever showed a correlation with the antibody level after the booster SARS-CoV-2 vaccine.

show abstract

Section: Discussionsupporting

confidence: 53%

Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This notion is supported by previous data from pre-SARS-CoV-2 vaccine era that showed a considerable degree of correlation between anti-N and anti-S IgG antibodies generated postinfection. 24 Our finding of poor correlations between antibodies and T-cell responses is consistent with some other studies showing no or low correlations between humoral and cellular immune parameters in vaccinated [25][26][27][28][29][30] and convalescent [31][32][33] individuals.…”

Section: Discussionsupporting

confidence: 92%

Immune response to 2-dose BNT162b2 vaccination and risk of SARS-CoV-2 breakthrough infection: The Shieldvacc-2 study

Seekircher

Bánki

Kimpel

et al. 2022

Preprint

View full text Add to dashboard Cite

It is uncertain to which extent antibody and T-cell responses after vaccination against SARS-CoV-2 are associated with reduced risk of breakthrough infection and whether their measurement enhances risk prediction. We conducted a phase-4 open-label clinical trial in the pre-omicron era, enrolling 2,760 individuals aged ≥16 years 35±8 days after having received the second dose of BNT162b2 (baseline 15-21 May 2021). Over a median 5.9-month of follow-up, we identified incident SARS-CoV-2 breakthrough infections using weekly antigen tests, a confirmatory PCR test, and/or serological evidence for incident infection. We quantified relative risks adjusted for age, sex, and prior SARS-CoV-2 infection for different immunological parameters and assessed improvements in risk discrimination. In contrast to the T-cell response, higher plasma levels of binding antibodies and antibodies in a surrogate neutralization assay were associated with reduced risk of breakthrough infection. Furthermore, assessment of anti-spike IgG levels enhanced prediction of breakthrough infection and may therefore be a suitable measurable correlate of protection in practice.

show abstract

“…A possible pathophysiological explanation for these results is the fact that IFN-γ secreted from specific T cells was not detected due to migration of SARS-CoV-2 specific memory T cells to lymphoid tissues, after a certain period of time [ 23 , 27 ]. After their encounter with SARS-CoV-2 antigens, T cells circulate in the blood secreting IFN-γ [23] .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity

Dourdouna

Tatsi

Syriopoulou

et al. 2023

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers

Cited by 8 publications

References 21 publications

Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme

Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme

Immune response to 2-dose BNT162b2 vaccination and risk of SARS-CoV-2 breakthrough infection: The Shieldvacc-2 study

Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity

Contact Info

Product

Resources

About